GBIO vs GSK · rev $19.9M vs P/E 13, $103.31B cap
Generation Bio Co (GBIO) versus GlaxoSmithKline PLC ADR (GSK) — a side-by-side from cached financials, not a winner call.
Generation Bio Co (GBIO) is a biotechnology company listed on US.
GlaxoSmithKline PLC ADR (GSK) is a drug manufacturers - general company listed on US.
Latest reported GBIO revenue for 2024-12-31 was $19.9M. Net income was -$131.7M. Revenue was up 236.9% from 2023-12-31 to 2024-12-31. GBIO currently screens at market cap $25.4M.
GSK does not have a complete income-statement cache yet.
GBIO currently screens at market cap $25.4M. GSK currently screens at market cap $103.31B and trailing P/E 13.5.
Not investment advice. Open the GBIO and GSK stock pages for the full models.
Not investment advice.